SCHEMBL15550758

SCHEMBL15550758

COc1c(C(N)=O)cccc1-c1nc2ccccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 9/20 0.60
KDM4E B2RXH2 3/20 0.58
RAB9A P51151 3/20 0.58
AMY1A P0DUB6 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.50
HPGD P15428 3/20 0.50
MAPT P10636 2/20 0.49
HTT P42858 2/20 0.49
PLA2G2A P14555 1/20 0.49
ALOX15 P16050 1/20 0.49
PTGS2 P35354 1/20 0.49
NPC1 O15118 2/20 0.49
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
HSD17B10 Q99714 1/20 0.49
FOXO1 Q12778 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15553301 0.89 KDM4E (0.71) PARP1KDM4ERAB9AAMY1ASMN1; SMN2
SCHEMBL15552332 0.85 KDM4E (0.55) KDM4ERAB9AAMY1ASMN1; SMN2HPGD
SCHEMBL15551551 0.85 KDM4E (0.55) PARP1KDM4ERAB9AAMY1ASMN1; SMN2
SCHEMBL30412663 0.84 RAB9A (0.75) PARP1KDM4ERAB9ASMN1; SMN2HPGD
SCHEMBL3698974 0.84 RAB9A (0.75) PARP1KDM4ERAB9ASMN1; SMN2HPGD
SCHEMBL28978359 0.83 SMN1; SMN2 (0.64) PARP1KDM4ERAB9ASMN1; SMN2HPGD
SCHEMBL30335387 0.83 SMN1; SMN2 (0.64) PARP1KDM4ERAB9ASMN1; SMN2HPGD
SCHEMBL17372933 0.82 RAB9A (0.63) PARP1KDM4ERAB9ASMN1; SMN2HPGD
SCHEMBL15552049 0.81 KDM4E (0.50) PARP1KDM4ERAB9AAMY1ASMN1; SMN2
SCHEMBL15550994 0.80 RAB9A (0.58) PARP1KDM4ERAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA PARP1 2164/4885KDM4E 3916/4885RAB9A 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.